Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States

Conclusion The increased risk of CVD observed in this real-world analysis of CML patients underscores the importance of current NCCN® recommendations to consider CV risk when selecting TKIs. Teaser Guidelines recommend that comorbidities, including CVD, be considered when selecting TKIs for the treatment of CML. An increased risk of CVD and its risk factors in CML patients treated by community-based US oncologists was identified in a real-world analysis of an EMR database (N=1,639). These results underscore the importance of current NCCN® recommendations to consider CV risk when selecting TKIs.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research